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Abstract
Early intervention in psychosis is crucial to improving patient response to treatment and the functional deficits that critically
affect their long-term quality of life. Stratification tools are needed to personalize functional deficit prevention strategies at an
early stage. In the present study, we applied topological tools to analyze symptoms of early psychosis patients, and detected a
clear stratification of the cohort into three groups. One of the groups had a significantly better psychosocial outcome than the
others after a 3-year clinical follow-up. This group was characterized by a metabolic profile indicative of an activated
antioxidant response, while that of the groups with poorer outcome was indicative of oxidative stress. We replicated in a
second cohort the finding that the three distinct clinical profiles at baseline were associated with distinct outcomes at follow-up,
thus validating the predictive value of this new stratification. This approach could assist in personalizing treatment strategies.
Introduction
Early intervention in psychosis is key to improving long-term
outcome [1–6], which is strongly influenced by quality of life
and social functioning trajectories in the early treatment phase
[7, 8]. Clinical and biological markers quantifying disease
course or treatment response should therefore be developed to
guide treatment decision at early stages of the disease [9–
12]. Since patient heterogeneity hampers marker identifica-
tion, stratification tools allowing personalized functional-
disability preventive strategies are needed.
Topological Data Analysis (TDA) is a powerful
approach to analyzing the shape of biological datasets,
identifying biotypes in a data-driven way. The TDA algo-
rithm Mapper produces graphical output that allows insight
into the robustness of the proposed stratification [13].
Mapper has shown promise for outcome assessment in
neurological trauma [14] and for detecting significant sub-
groups of breast cancers. Applied to fragile X-syndrome
[15], structural brain images, Mapper identified distinct
subgroups with consistent cognition, adaptive functioning,
and autism severity scores.
In this study, we used TDA to stratify a cohort of early
psychosis patients based on Positive and Negative Syn-
drome Scale (PANSS) scores. Although clustering algo-
rithms were used previously to study symptom patterns
[16], this is the first such application of TDA. TDA strati-
fied the early psychosis cohort into three groups with
coherent clinical profiles. We then sought a biosignature of
the groups, representing distinct underlying pathophysio-
logical pathways. To test the hypothesis of redox dysregu-
lation/oxidative stress as one pathophysiological hub [17–
20], we studied redox markers such as blood levels of
glutathione (GSH), GSH peroxidase and reductase activities
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(GPx, GR), thioredoxin (Trx), and GSH-related metabolites.
In addition, we explored an unbiased selection of 28 amino
acids of which metabolism is notably altered both at schi-
zophrenia onset and in later stages [21–25].
To validate the clinical relevance of our stratification, we
compared outcomes after 3 years between groups, focusing
on functional level for three reasons. First, functional
recovery, the main determinant of the social and economic
burdens of schizophrenia [7], may fail despite symptom
remission. Second, functional level in the early illness phase
is relatively stable over 20 years [7] and the strongest pre-
dictor of later functional level [26]. The 3-year follow-up in
our study is thus likely to predict longer-term outcomes.
Finally, functional impairment, reported in all forms of
psychosis [7], is an important indicator for individuals at
risk for psychosis [27]. Better knowledge of its determi-
nants is therefore useful at various stages of the illness.
Materials/subjects and methods
Participants
All subjects provided a fully informed written consent; all
procedures were in accordance with the ethical standards of
the Helsinki Declaration (1983) and approved by the local
ethical committee. EPP were recruited from the Treatment
and early Intervention in Psychosis Program (TIPP2, see
Supplementary). Cohort 1 comprises 101 patients from the
TIPP program (biomarkers project, globally representative
of the entire cohort [28]) and cohort 2 comprises 93 TIPP
patients (not included in the biomarker study).
Clinical evaluations
Psychopathological assessments were conducted by trained
psychologists. We used the PANSS and the Wallwork five-
factor model to assess symptom severity and to categorize
the different symptom domains [29].
Outcomes at discharge were evaluated at 36 months or
within the last year of treatment: (i) ‘Working’: Modified
Vocational Status Index [30]; (ii) ‘Living independently’:
Modified Location Code Index [30]; (iii) symptomatic
remission: Andreasen criteria [31]; (iv) Social and Occu-
pational Functioning Assessment Scale (composite global
score; SOFAS) [32]; (v) Global Assessment of Functioning
(global composite score; GAF) [32].
TDA stratification of cohort 1 with Mapper
algorithm
We used the Mapper algorithm [33] (www.ayasdi.com) to
visualize and study the 30 PANSS items at baseline, using
(i) distance: normalized Pearson correlation distance; (ii)
filter function: coefficients in the coordinate system given by
the first two principal components; (iii) resolution: 60, (iv)
gain: 7. Our choice of resolution and gain is not crucial for
the identification of the Mapper-based partition [A, B, C], as
these groups are easily recognizable whenever the Mapper
graph does not have trivial connectivity structure (Supple-
mentary Fig. 1, Supplementary Methods).
Assessment of metabolic markers
Amino acids were quantified in plasma [34], and GSH and
GPx, GR, and Trx activity levels in blood cell pellets after
hemolysis [35–37] (Supplementary Methods). Two meta-
bolites are considered strongly correlated in a group of
patients if the Pearson correlation between the associated
vectors is significantly different from zero (p value < 0.05).
Biological correlations among the 28 measured metabolites
in cohort 1 were determined in groups A, B, or C as detailed
in the Supplementary.
Validation of the stratification in cohort 2
An independent cohort of 93 individuals, called cohort 2,
was used for validation. We computed the centroid of the
symptom vectors of each group in cohort 1, i.e., the average
value, within the group, of each coordinate in the 30-
dimensional space of PANSS scores. We then computed the
Euclidean distance between the symptom vector of each
patient in cohort 2 and the centroids of the groups from
cohort 1, assigning the patient to the group with the closest
centroid. This assignment determined a partition of cohort 2
into subgroups, called the replicated groups.
Prediction of good vs. poor functional outcome
We used logistic regression to predict good vs. poor
functional outcome (GAF > 65 vs. GAF ≤ 65), based on
either the PANSS items or group membership in [A, B, C]
or [0, 1, 2]. We trained on cohort 1, validated on cohort 2,
and evaluated the accuracy, precision, and recall of the
regression, as implemented in the sklearn library. See the
Supplementary and Supplementary Table 1 for more
details.
Group comparisons for clinical and metabolic data
We used the Kolmogorov–Smirnov test, as implemented in
the python function ‘scipy.stats.ks_2samp’ from the scipy
library, to identify which PANSS items are group-specific.
For each PANSS item, we compared the distribution of its
scores in one group with the distribution in the remaining
two groups by the Kolmogorov–Smirnov test and applied
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Bonferroni correction for multiple comparisons. Items were
considered as group-specific if the corrected p value < 0.05.
We computed Pearson correlation coefficients to create
correlation matrices of metabolite levels in patients within
groups A, B, or C, using the function corrcoef(), in the
numpy python library. All other statistics were performed
with R, using the Chi-Square test for independence to
compare distributions and Student’s t test or analysis of
variance to compare continuous variables between two or
three groups, respectively. If not otherwise specified, groups
were considered different when p < 0.05.
k-means clustering
We performed k-means clustering via sklearn.cluster.
KMeans implemented in the python library sklearn. We
chose k= 3, to be able to compare with the three TDA-
based groups.
Results
Stratification of cohort 1 by TDA based on symptom
levels at baseline
Cohort 1 was composed of 101 patients treated in an early
intervention program (TIPP2). Patients were primarily
males, with a mean age of 25.1 years and a mean illness
duration of 1.9 years at baseline (Table 1). Most patients
were prescribed antipsychotics (95%).
We used the Mapper algorithm to visualize the data
quantifying the severity of symptoms. We associated to
each patient a vector of 30 entries recording the PANSS
items’ scores. The Mapper algorithm was then used to
cluster the vectors, forming the nodes of a graph. A vector
can belong to more than one node; if two nodes share at
least one vector, they are connected by an edge. By con-
struction, vectors representing patients with similar
symptom values at baseline belong to the same node or to
a set of tightly connected nodes of the Mapper graph
(Fig. 1a).
From the shape of the Mapper graph generated from the
PANSS items, we identified three groups of patients: group
A (n= 21), group B (n= 30), and group C (n= 43;
Fig. 1a), with similar mean age, age at illness onset, and
proportion of males/females (Fig. 1d). A small number of
patients were not classified (n= 7, Supplementary Table 2).
At recruitment, positive and excited symptoms were highest
for group B (Fig. 1b, c); patients in group B had more
elevated scores for many items of the positive and general
PANSS than the rest of the cohort (e.g., P1, P3, G9; Sup-
plementary Table 3). Negative and depressed symptoms
were lowest in group A; low scores for negative and
depressed symptoms characterized group A (e.g., N1, N2,
G6). Higher scores on negative symptoms (e.g., N1, N2)
distinguished group C from the rest of the cohort. Dis-
organized symptoms were high in group B, intermediate in
group C, and low in group A.
We further explored blood metabolites, since the iden-
tification of biomarkers correlated with outcome might lead
to the identification of target metabolic pathways.
Biomarkers characterizing the clinical groups at
baseline
Two groups of compounds were quantified at baseline: (1)
redox-related metabolites and enzyme blood levels (GSH,
GPx, GR, and Trx activities [34, 36]), and (2) 28 free amino
acids and derivatives (Supplementary Table 4).
GPx activity was lower in group A (23.3 ± 1.9 µmol/min/
gHb) than in B and C, respectively (25.5 ± 1.9, p= 0.047
and 28.1 ± 1.6 µmol/min/gHb, p= 0.008; Fig. 2), while that
of GR and Trx was similar in the three groups. Group A
tended to have increased levels of the antioxidant GSH
than group B (p= 0.062). Group A displayed higher 2-
aminobutyrate levels (21.4 ± 2.1 µM) than B and C,
respectively (17.9 ± 1.2 µM, p= 0.046 and 16.8 ± 1.0 µM,
p= 0.009; Fig. 2). To further explore whether metabolic
pathways related to these proteinogenic amino acids were
differentially regulated in the three groups, we studied the
correlations between metabolites that correspond to known
biological pathways. In group A, the metabolism of nitric
oxide and of methionine was affected (urea cycle and
arginine, proline metabolism, Fig. 3 and Supplementary
Fig. 2). Strikingly, many amino acids were correlated to
glutamate levels in group C, possibly reflecting amino acid
degradation, as the first step involves transamination to
form glutamate [38].
Table 1 Demographics.
Cohort 1 (n= 101) mean [range] Cohort 2 (n= 93) mean [range] p value (test statistic)
% Male (male/female) 76.2% (77/24) 55.9% (52/41) p= 0.005 (χ2= 8.09)
Age at evaluation (years) 25.1 [17.1–38.2] 25.4 [18–35] p= 0.75 (t=−0.32)
Illness duration (years) 1.9 [0–5] 2.0 [0–18] p= 0.82 (t=−0.22)
Age at psychosis (years) 23.1 [13.6–38.0] 23.5 [14–35] p= 0.68 (t= 0.42)
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Predictive value of the grouping for the outcome at
discharge
Clinical follow-up assessments included symptom levels,
diagnosis, symptomatic remission [31], global and social
functioning (GAF; SOFAS), and whether the patient was
working or living independently at the end of 3 years of
treatment [30].
At follow-up, most symptoms had reached similarly low
levels in all three groups (Fig. 4c); the exceptions were the
negative symptoms, which remained higher in group C
(12.6 ± 1.2) than in group A (7.4 ± 1.0; p= 0.005). Patients
from group B were more frequently diagnosed with schi-
zophrenia (Fig. 4a) and those from group A with schizo-
phreniform disorder or brief psychosis episode. Patients
from group A had better social functioning (SOFAS) than
groups B and C, and better global functioning (GAF) than
group C. (Fig. 4b). Varying the position of the boundary
between groups B and C did not affect the profiles specific
to each group at inclusion, and mostly preserved the dif-
ferences of outcome (Supplementary Fig. 3).
We used machine learning with logistic regression to
quantify the predictive power of this new stratification for
good or poor psychosocial functioning at outcome (i.e.,
GAF > 65 or ≤65). Logistic regression was performed on
either PANSS scores at baseline or membership in groups A,
B, and C (Supplementary Table 1). The accuracy of logistic
regression using the PANSS items was poor (precision: 0.20;
recall: 0.05), but was 0.74 when using group membership
instead (precision: 0.68; recall: 0.46; Supplementary Fig. 4c).
In summary, TDA of PANSS symptoms at baseline
identified three clinically distinct groups of early psychosis
Fig. 1 Identification of three clinical profiles at baseline. a Mapper
graph based on the symptoms of early psychosis patients. Each node
represents a group of patients. Each edge represents at least one
common patient between the two connected nodes. Nodes are colored
according to mean PANSS positive score. The dashed line represents
the separation between groups B and C. The dashed circle highlights
the two isolated nodes (n= 4 patients in total) who were not assigned
to any group. b The Mapper graphs are colored according to the scores
for the subscales of the Wallwork five-factor model. c Box plots
illustrating the levels of symptoms at recruitment in groups A (white),
B (gray), and C (blue) for the subscales of the Wallwork five-factor
model. *p < 0.05 d Demographic characteristics of groups A, B, and
C. Data are presented as mean (standard error).
Fig. 2 Metabolic characterization of the three clinical profiles at
baseline. Boxplot illustrating the blood levels of three antioxidant
enzymes (Glutathione peroxidase (GPx), Glutathione reductase (GR),
Thioredoxin), of glutathione (GSH), and a modulator of GSH meta-
bolism, 2-aminobutyrate. *p < 0.05 using a linear model adjusted for
age and sex.
Topology predicts long-term functional outcome in early psychosis
patients with predictive value for functional outcome at
3 years.
Validation study in cohort 2
A replication cohort of 93 TIPP patients was constituted
(cohort 2), matched for age at illness onset, illness duration,
and age at baseline; its proportion of females was higher
(Table 1).
Patients from the cohort 2 were assigned to replication
groups based on the distance of their symptom vectors to
the centroids of groups A, B, and C (Supplementary Fig. 5).
For instance, a patient whose symptom vector was closer to
the average symptoms in group A than to that of the other
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Fig. 3 Metabolic pathways and the corresponding metabolites that are correlated for each clinical group (all correlations are positive). →
or↔: uni- or bi-directional metabolic reaction. Colored edges connect pairs of metabolites that are strongly correlated among patients (p < 0.05) in
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Note that the pattern of correlated amino acids differed between groups, and stronger correlations among a larger group of amino acids were
detected in group A than in groups B and C (Supplementary Fig. 2). When we consider only the correlations that correspond to known biological
pathways. (https://www.vmh.life/), the regulation of various systems appeared to be differentially impaired in the three groups. hyp hydroxy-
proline, cit citrulline, orn ornithine.
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groups was assigned to replication-group A (rep-A). For the
three replication groups from cohort 2, the number of
patients, mean age, age at illness onset, and proportion of
males/females were similar to those of cohort 1 (Fig. 5a).
The baseline symptoms characterizing each group were
reproduced in cohort 2 at the factor level (Fig. 5b) and at the
item level (Supplementary Table 3).
Outcome in the validation study
The outcomes of patients in rep-A were better than those
of rep-B for all the criteria assessed (Fig. 6b). Mean
functioning scores (GAF, SOFAS) were different among
the three groups: lowest in rep-B and highest in rep-A.
The group rep-A had the best outcome after 3 years of
clinical follow-up, while rep-B had the worst outcome, as
in cohort 1 (see Fig. 4b for comparison). There were two
significant differences from cohort 1: (i) the retained
diagnoses were similar among the predicted groups
(Fig. 6a); (ii) the group rep-C had a better outcome than
group C, displaying an intermediate profile, between rep-A
and rep-B.
We trained logistic regression to predict good vs. poor
functional outcome on cohort 1 and tested it on cohort 2.
Fig. 4 Outcomes associated
with the three clinical profiles
at discharge for cohort 1. a
Table summarizing the retained
diagnosis. The Chi-Square test
for independence indicates a
difference among the groups in
the proportion of diagnosis.
Brief Psychotic Ep.: brief
psychotic episode. b Bar graph
illustrating the percentages of
patients from groups A, B, and
C who are working, living
independently, or in
symptomatic remission, and the
score for the SOFAS (Social and
Functional Assessment scale)
and GAF (Global Assessment of
Functioning) scales. *p < 0.05.
c Temporal evolutions of
symptoms in cohort 1. Scores
for the subscales of the
Wallwork five-factor model in
groups A (light gray), B (dark
gray), and C (blue).Lines: Mean
value, Shaded color: 95%
confidence interval.
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Fig. 5 Replication of the three clinical profiles in cohort 2. a Table
summarizing the demographic characteristics of the predicted groups
in the validation cohort 2. Data are presented as mean (standard error).
b Bar graph representing the levels of symptoms at recruitment in
predicted groups A (white), B (gray), and C (blue) using Wallwork
five-factors model. *p < 0.05.
Fig. 6 Replication of the outcomes associated with the three clin-
ical profiles. a Table summarizing the retained diagnoses of patients in
the validation cohort. The Chi-Square test for independence indicates a
difference between groups in the proportion of diagnosis. Brief Ep.:
brief psychotic episode. b Bar graph illustrating the percentage of
patients in the validation cohort from predicted groups A, B, and C
who are working, living independently, or in symptomatic remission,
and the score for the SOFAS and GAF scales. *p < 0.05. c Precision-
recall curve of Logistic Regression, with regularization strength 1,
when using PANSS items (red), TDA-based group membership (blue),
k-means clustering (purple), or k-means clustering on PCA (green).
The dashed line represents the proportion of patients with good out-
come in cohort 2, i.e., the precision of the model that always predicts
good outcome.
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Using TDA-based groups as features, rather than PANSS
items, we obtained better accuracy, precision, and recall
scores (Supplementary Fig. 4a). The area under the
precision-recall curve for PANSS items was 0.46, compared
with 0.61 for the TDA-based groups (Fig. 6c). Overall, we
validated with cohort 2 the clinical and demographic pro-
files of cohort 1. Logistic regression confirmed the robust
predictive value of group A for long-term functional
outcomes.
Comparing topological clustering to a standard
clustering method
To assess the originality of our clustering and confirm that
we identify a robust structure in the data, we compared the
TDA-based stratification of cohort 1 into groups A, B, and
C, to the partition [0, 1, 2] or [0PCA, 1PCA, 2PCA] obtained by
clustering the same data with the k-means algorithm (K= 3)
or by clustering the two first principal component scores of
the data with k-means (K= 3).
The k-means clusters [0, 1, 2] partly overlapped with the
TDA-based groups (Supplementary Fig. 6). However, the
predictive power of the partition [0, 1, 2] was lower than
that of the TDA groups [A, B, C], according to all the
metrics considered to evaluate the performance of logistic
regression (Fig. 6c and Supplementary Fig. 4). The k-means
clustering on PCA produces intermediate results between
the k-means and the TDA-based groups. The clusters [0PCA,
1PCA, 2PCA] partly overlapped with the TDA-based groups
(Supplementary Fig. 7). The predictive power of the parti-
tion [0PCA, 1PCA, 2PCA] was good when using cohort 1 as
training set and cohort 2 as test set, but lower than that of
the TDA groups [A, B, C] for the fivefold cross validation
scheme (Fig. 6c and Supplementary Fig. 4).
Discussion
Applying TDA to stratify a cohort of early psychosis
patients (n= 101) according to their symptom levels, we
identified three clinical profiles displaying distinct biologi-
cal characteristics and different long-term functional out-
come. Group A was characterized by an overall low level of
symptoms and favorable functional outcome, while group B
(with high positive and negative symptoms), and group C
(with high negative symptoms) had poorer functional out-
come. In a validation cohort (n= 93), we confirmed that
predicted group membership is associated with distinct
clinical profiles at baseline and at follow-up. TDA grouping
also predicted good vs poor functional outcome with higher
accuracy than the PANSS items or groups obtained by k-
means clustering, confirming the clinical relevance of the
TDA grouping.
Regarding redox markers, group A displayed a distinct
metabolic profile, with the lowest GPx activity compared
with groups B and C. As high blood GPx activities are
associated with low brain GSH levels [37], this result sug-
gests that better outcome within group A may be related to
better redox regulation and poorer outcome in B and C to
high oxidative status and/or an important redox dysregula-
tion [18, 36]. Interestingly, the exploratory profiling of
amino acids highlighted that 2-aminobutyrate levels were
higher in group A than in B and C. 2-Aminobutyrate,
proposed as marker for GSH dynamics [39–41], is a
byproduct of cysteine, the limiting precursor of GSH, which
modulates GSH homeostasis. These observations suggest a
correlation between better regulation of antioxidant defense
and better outcome (Supplementary Fig. 8). The correla-
tions between urea cycle metabolites differed between
group A versus B and C, suggesting a difference in reac-
tions distributed between the mitochondrial matrix and the
cytosol. The previously reported urea cycle dysregulation,
as well as decreased arginine levels and nitric oxide
imbalance in schizophrenia, may thus be more prominent in
subgroups B and C [22, 24, 42].
Interpretation of the metabolic profile is hindered by our
selection, which was oriented toward the assessment of
redox balance. Inflammatory markers, lipid metabolism,
NMDA receptor reactivity, and dopamine functions should
also be examined, as should the potential effect of medi-
cation, since antipsychotics may alter amino acid metabo-
lism [21]. Moreover, replication is needed to strengthen
these conclusions, as blood was not available in our vali-
dation cohort.
The robustness of the TDA-identified groups was
established by several tests: (i) the groups remained cohe-
sive for different parameters and different implementations
of the Mapper algorithm (Supplementary Fig. 1); (ii) pro-
files at inclusion and outcomes were stable when changing
slightly the boundary between groups; (iii) most results
were similar in both cohorts of early psychosis patients; and
(iv) the k-means clustering stratification was similar to the
TDA stratification, although k-means clusters overall had a
lower predictive value for outcome. Compared with other
stratification methods, an important advantage of Mapper is
the graph structure visualization: connectivity variations
when modifying the resolution and gain parameter were
important for developing intuition about the relation
between groups and their composition at different scales.
Other group-assignment strategies that take into account the
Mapper structure may improve group identification.
The finding that group A had better outcome was data
driven and is therefore a robust finding. The low levels of
symptoms in this group may indicate a good early response
to treatment, associated with better functioning [11, 43, 44],
and improved long-term outcome [45, 46]. The fact that
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patients with poor functional outcome split into two groups
is also of importance, as different therapeutic strategies
might be required, based on the clinical and metabolic
profiles. Though group B was characterized by high posi-
tive symptoms at baseline, it did not include more
treatment-resistant patients than those of group C, which
present low positive symptoms at baseline (Supplementary
Table 5). Furthermore, the observation that all three groups
displayed similarly low levels of positive symptoms at the
end of the clinical follow-up suggests that patients in group
B are slow/poor responders to treatment and may need
intensive case management or specific antipsychotic drug
[8, 47]. Group B has neither patients with bipolar disorder
nor with schizophreniform disorder and its less favorable
outcome is in line with previous papers showing that schi-
zophrenia has poorer outcome than affective psychoses or
schizophreniform disorder [48, 49].
Negative symptoms are known to be associated with
poor outcomes [50] and difficult to treat. Patients from
groups B and C displayed high levels of negative symptoms
at baseline, though these symptoms remain high only in
group C. This may be linked to a different illness profile and
neurobiological basis between groups B and C, which is
actually in line with our results showing that they have
distinct metabolic profiles. Group C may consist of patients
with persistent trait-related negative symptoms, known
indicators of poor psychosocial outcome [51–53]. The GPx
activity was particularly high in group C, suggesting that
they may benefit from antioxidant add-on therapy [35] such
N-acetyl-cysteine, which improves negative symptoms
[54, 55]. Despite the limitations of the tools used to assess
negative symptoms our results suggest that on their basis it
is possible to identify distinct subgroups of patents with
distinct needs.
In summary, unsupervised data-driven topological ana-
lysis of symptoms produced meaningful stratification of
early psychosis patients and detected patients at risk of poor
functional and social outcomes. Although this study
requires replication in patient populations recruited at dif-
ferent sites, this approach, combined with mechanism-based
metabolic profiling, should pave the way for personalized
functional-disability preventive strategies at early stages of
the disease.
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